IL2 and systemic lupus erythematosus: More recently, results have been reported from an international, double-blind, placebo-controlled phase 2 clinical trial (LUPIL-2) with low-dose IL-2 therapy (aldesleukin, ILT-101) in moderately-to-severely active SLE patients.[52] This multi-center trial included 36 sites from 10 different countries and aimed to assess safety, clinical efficacy, and biological responses.